Preclinical efficacy of THRX-200495, a dual pharmacology muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA)

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 5, 2012, Pages 357-363

  McNamara, Alexander ^a   Steinfeld, Tod ^a   Pulido Rios, Maria Teresa ^a   Stangeland, Eric ^a   Hegde, Sharath S ^a   Mammen, Mathai ^a   Martin, William J ^a  

^a THERAVANCE INC   (United States)

Author keywords

2 Adrenoceptor; Albuterol; COPD; Ipratropium; MABA; Muscarinic

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; HISTAMINE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; METHACHOLINE; MUSCARINIC RECEPTOR BLOCKING AGENT; PROPRANOLOL; THRX 200495; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BRONCHOPROTECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GUINEA PIG; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG PRESSURE; MALE; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; PROTECTION; TRACHEOTOMY; VENTILATION PRESSURE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; BRONCHI; CARBAMATES; GUINEA PIGS; HISTAMINE RELEASE; MALE; METHACHOLINE CHLORIDE; MUSCARINIC ANTAGONISTS; QUINOLONES;

EID: 84865955542     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.06.007     Document Type: Article

References (43)

1. Barnes P.J., Belvisi M.G., Mak J.C.W., El Haddad B., O'Connor B. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995, 56:853-859.
2. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789. 22.
3. Cazzola M., Centanni S., Santus P., Verga M., Mondoni M., di Marco F., et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004, 98(12):1214-1221.
4. 2-agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2005, 2:305-310.
5. 3-muscarinic and beta(2)-adrenergic receptors at the level of receptor phosphorylation and desensitization. Mol Pharmacol 1999, 56(4):813-823.
6. McGraw D.W., Elwing J.M., Fogel K.M., Wang W.C., Glinka C.B., Mihlbachler K.A., et al. Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation. J Clin Invest 2007, 117(5):1391-1398.
7. 2-adrenoreceptor and muscarinic acetylcholine receptor: implications for gene-gene interactions and bronchodilatory responses in patients with asthma and COPD. Curr Pharmacogenomic Person Med 2008, 6:302-319.
8. van Noord J.A., Aumann J.L., Janssens E., Verhaert J., Smeets J.J., Mueller A., et al. Effects of tiotropium with and without formoterol on airflow and resting hyperinflation in patients with COPD. Chest 2006, 129:509-517.
9. van Noord J.A., Aumann J.L., Janssens E., Smeets J.J., Zaagsma J., Mueller A., et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med 2010, 104(7):995-1004.
10. Tashkin D.P., Varghese S.T. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm Pharmacol Ther 2011, 24(1):147-152.
11. Gold P.M. The 2007 GOLD guidelines: a comprehensive care framework. Respir Care 2009, 54:1040-1049.
12. Weder M.M., Donohue J.F. Role of bronchodilators in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005, 26:221-234.
13. Dorinsky P.M., Reisner C., Ferguson G.T., Menjoge S.S., Serby C.W., Witek T.J. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999, 115(4):966-971.
14. Gross N., Tashkin D., Miller R., Oren J., Coleman W., Linberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration 1998, 65(5):354-362.
15. Toy E.L., Beaulieu N.U., McHale J.M., Welland T.R., Plauschinat C.A., Swensen A., et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011, 105:435-441.
16. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545-555.
17. Vogelmeier C., Kardos P., Harari S., Gans S.J., Stenglein S., Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008, 102(11):1511-1520.
18. Tashkin D.P., Littner M., Andrews C.P., Tomlinson L., Rinehart M., Denis-Mize K. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med 2008, 102(4):479-487.
19. van Noord J.A., Buhl R., Laforce C., Martin C., Jones F., Dolker M., et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010, 65:1086-1091.
20. NCT: Clinicaltrials.gov (NCT ID: 01313637).
21. Welte T., Miravitlles M., Hernandez P., Eriksson G., Peterson S., Polanowski T., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:741-750.
22. Jacobsen J.R., Aiyar J., Hegde S., Hughes A.D., Mammen M. Dual pharmacology bronchodilators for the treatment of COPD. Prog Respir Res Basel Karger 2010, 39:39-45.
23. Hughes A.D., Jones L.H. Dual-pharmacology muscarinic antagonist and β agonist molecules for the treatment of chronic obstructive pulmonary disease. Future Med Chem 2011, 3:1585-1605.
24. Steinfeld T., Hughes A.D., Klein U., Smith J.A., Mammen M. THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol 2011, 79:389-399.
25. Hughes A.D., McNamara A., Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and β(2) agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012, 51:71-95.
26. Yoshizaki S., Tanimura K., Tamada S., Yabuuchi Y., Nakagawa K. Sympathomimetic amines having a carbostyril nucleus. J Med Chem 1976, 19:1138-1142.
27. Milecki J., Baker S.P., Standifer K.M., Ishizu T., Chida Y., Kusiak J.W., et al. Carbostyril derivatives having potent beta-adrenergic agonist properties. J Med Chem 1987, 30:1563-1566.
28. Naito R., Takeuchi M., Morihira K., Hayakawa M., Ikeda K., Shibanuma T., et al. Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives. Chem Pharm Bull 1998, 46:1286-1294.
29. McNamara A., Pulido-Rios M.T., Hegde S.S., Martin W.J. Application of the classical Einthoven model of bronchoconstriction to the study of inhaled bronchodilators in rodents. Pharmacol Toxicol Methods 2011, 63:89-95.
30. January B., Seibold A., Allal C., Whaley B.S., Knoll B.J., Moore R.H., et al. Salmeterol-induced desensitization, internalization and phosphorylation of the human β2-adrenergic receptor. Br J Pharmacol 1998, 123:701-711.
31. Friedman M., Serby C.W., Menjoge S.S., Wilson J.D., Hilleman D.E., Witek T.J. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999, 115:635-641.
32. 50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
33. Fryer A.D., Maclagan J. Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea pig. Eur J Pharmacol 1987, 139:187-191.
34. Mohammed S.P., Taylor C.V., Weyman-Jones C.B., Mather M.E., Vendy K., Dougall I.G., et al. Duration of action of inhaled vs. intravenous beta(2)-adrenoceptor agonists in an anaesthetized guinea-pig model. Pulm Pharmacol Ther 2000, 13:287-292.
35. Villetti G., Bergamaschi M., Bassani F., Bolzoni P.T., Harrison S., Gigli P.M., et al. Pharmacological assessment of the duration of action of glycopyrrolate vs. tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol 2006, 148:291-298.
36. Zainudin B.M., Biddiscombe M., Tolfree S.E., Short M., Spiro S.G. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990, 45(6):469-473.
37. Osier M., Oberdörster G. Intratracheal inhalation vs intratracheal instillation: differences in particle effects. Fundam Appl Toxicol 1997, 40(2):220-227.
38. Rossoni G., Manfredi B., Razzetti R., Civelli M., Berti F. Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs. Pulm Pharmacol Ther 2007, 20:250-257.
39. Rogers D.F. Motor control of airway goblet cells and glands. Respir Physiol 2001, 125:129-144.
40. Mita Y., Dobashi K., Suzuki K., Mori M., Nakazawa T. Induction of muscarinic receptor subtypes in monocytic/macrophagic cells differentiated from EoL-1 cells. Eur J Pharmacol 1996, 297:121-127.
41. Sato E., Koyama S., Okubo Y., Kubo K., Sekiguchi M. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol 1998, 274:L970-L979.
42. Jeffery P.K., Venge P., Gizycki M.J., Egerod I., Dahl R., Faurschou P. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002, 20:1378-1385.
43. Lagente V., Naline E., Guenon I., Corbel M., Boichot E., Burgaud J.L., et al. A nitric oxide-releasing salbutamol elicits potent relaxant and anti-inflammatory activities. J Pharmacol Exp Ther 2004, 310:367-375.